Acetylator phenotype in relation to age and gender in the baltimore longitudinal study of aging

Journal of Clinical Pharmacology

Volumn 37, Issue 2, 1997, Pages 83-91

  Korrapati, Madhu R ^a,b   Sorkin, John D ^c   Andres, Reubin ^c   Muller, Denis C ^c   Loi, Cho Ming ^a,d   Vesell, Elliot S ^e   Vestal, Robert E ^a,b,f,g  

^a Clin Pharmacol Gerontology Res U   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d IDAHO STATE UNIVERSITY   (United States)

^e PENN STATE COLLEGE OF MEDICINE   (United States)

^f St Luke's Mountain States Tumor Institute   (United States)

^g Boise VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLDAPSONE; ACYLTRANSFERASE; DAPSONE;

ACETYLATION; ACETYLATOR PHENOTYPE; ADULT; AGED; AGING; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME ACTIVITY; FEMALE; HISTOGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; SEX DIFFERENCE;

EID: 0030951759     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04765.x     Document Type: Article

References (41)

1. Weber WW, Hein DW: N-acetylation pharmacogenetics. Pharmacol Rev 1985;37:25-79.
2. Evans DAP: N-Acetyltransferase. In, Kalow W (ed.): Pharmacogenetics of Drug Metabolism. New York: Pergamon Press, 1992;95-178.
3. Lunde PKM, Frislid K, Hansteen V: Disease and acetylation polymorphism. Clin Pharmacokinet 1977;2:182-197.
4. Clark, DWJ: Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs 1985;29:342-375.
5. Drayer DE, Reidenberg MM: Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharamacol Ther 1977;22:251-258.
6. Cartwright RA, Glashen RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Khan M: Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982;11:842-846.
7. Hanke J, Krajewska B: Acetylation phenotypes and bladder cancer. J Occup Med 1990;32:917-918.
8. Ellard GA: Variations between individuals and populations in the acetylation of isoniazid and it significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther 1976;19:610-625.
9. Kalow W: Ethnic differences in drug metabolism. Clin Pharmacokinet 1982;7:373-400.
10. Gachalyi B, Vas A, Hajos P, Kaldor A: Acetylator phenotypes: effect of age. Eur J Clin Pharmacol 1984;26:43-45.
11. Paulsen O, Nilsson LG: Distribution of acetylator phenotype in relation to age and sex in Swedish patients. Eur J Clin Pharmacol 1985;28:311-315.
12. Pontiroli AE, De Pasqua A, Bonisolli L, Pozza G: Ageing and acetylator phenotype as determined by administration of sulphadimidine. Eur J Clin Pharmacol 1985;28:485-486.
13. Philip PA, Gayed SL, Rogers HJ, Crome P: Influence of age, sex and body weight on the dapsone acetylation phenotype. Br J Clin Pharmacol 1987;23:709-713.
14. Siegmund W, Hanke W, Zschiesche M, Franke G, Biebler KE, Wilke A: N-acetylation and debrisoquine type oxidation polymorphism in Caucasians - with reference to age and sex. Int J Clin Pharmacol Ther Toxicol 1990;28:504-509.
15. Relling MV, Lin JS, Ayers GD, Evans WE: Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP 1A2 activities. Clin Pharmacol Ther 1992;52:643-658.
16. May GD, Porter J, Wilkinson GR, Branch RA: Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther 1994;55:492-500.
17. Hanson A, Melander A, Wahlin-Boll E: Acetylator phenotyping: a comparison of the isoniazid and dapsone tests. Eur J Clin Pharmacol 1981;20:233-234.
18. Shock NW, Greulich RC, Andres R, Arenberg D, Costa PT Jr, Lakatta EG, Tobin JD: Normal Human Aging: The Baltimore Longitudinal Study of Aging (NIH Publication No.84-2450). Washington: US Government Printing Office, 1984;45-62.
19. Carr K, Oates JA, Nies AS, Woosley RL: Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype. Br J Clin Pharmacol 1978;6:421-427.
20. Engelman L: Maximum likelihood estimation. In, Dixon WJ, Brown MB, Jennrich RI, (eds.): BMDP Statistical Software Manual, Volume 2. Berkeley: University of California Press, 1990;721-738.
21. Vatsis KP, Weber WW, Bell DA, Dupret J-M, Evans DAP, Grant DM, et al: Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17.
22. Vatsis KP, Weber WW: Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 1993;301:71-76.
23. Hickman D, Sim E: N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol 1991;42:1007-1014.
24. Hein DW, Rustan TD, Doll MA, Bucher KD, Ferguson RJ, Feng Y, et al: Acetyltransferases and susceptibility to chemicals. Toxicol Lett 1992;64:123-130.
25. Evans DAP, Manley KA, McKusick VA: Genetic control of isoniazid metabolism in man. BMJ 1960;2:485-491.
26. Sim E, Hickman D: Polymorphism in human N-acetyltransferase - the case of the missing allele. Trends Pharmacol Sci 1991;12:211-213.
27. Brennan RW, Dehejia B, Kutt H, Verebely K, McDowell F: Diphenylhydantoin intoxication attendant to slow inactivation of isoniazid. Neurology 1970;20:687-693.
28. Kirlin WG, Ogolla F, Andrews AF, Trinidad A, Ferguson RJ, Yerokun T, et al: Acetylator genotype dependent expression of arylamine N-acetyltransferase in human colon cytosol from noncancer and colorectal cancer patients. Cancer Res 1991;51:549-555.
29. Cheminat JC, Paire M, Lavarenne J, Ducarrouge C, Molina C: Value of determining plasma INH during antitubercular treatment. Retrospective analysis of 204 cases. Rev Fr Mal Respir 1983;11:867-873.
30. Kergueris MF, Bourin M, Larousse C: Pharmacokinetics of isoniazid: influence of age. Eur J Clin Pharmacol 1986;30:35-40.
31. Hildebrand M, Seifert W: Determination of acetylator phenotype in Caucasians with caffeine. Eur J Clin Pharmacol 1989;37:525-526.
32. El-Yazigi A, Chaleby K, Martin CR: Acetylator phenotypes in Saudi Arabians by a simplified caffeine metabolites test. J Clin Pharmacol 1989;29:246-250.
33. Bozkurt A, Basci NE, Kalan S, Tuncer M, Kayaalp SO: N-acetylation phenotyping with sulfadimidine in a Turkish population. Eur J Clin Pharmacol 1990;38:53-56.
34. Farah F, Taylor W, Rawlins MD, James O: Hepatic drug acetylation and oxidation: effects of aging in man. BMJ 1977;2:155-156.
35. Iselius L, Evans DAP: Formal genetics of isoniazid metabolism in man. Clin Pharmacokinet 1983;8:541-544.
36. Horai Y, Zhou HH, Zhang LM, Ishizaki T: N-acetylation phenotyping with dapsone in a mainland Chinese population. Br J Clin Pharmacol 1988;25:81-87.
37. Horai Y, Ishizaki T: N-acetylation polymorphism of dapsone in a Japanese population. Br J Clin Pharmacol 1988;25:487-494.
38. Horai Y, Fujita K, Ishizaki T: Genetically determined N-acetylation and oxidation capacities in Japanese patients with nonoccupational urinary bladder cancer. Eur J Clin Pharmacol 1989;37:581-587.
39. Cascorbi I, Drakoulis N, Bröckmoller J, Maurer A, Sperling K, Roots I: Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995;57:581-592.
40. Bechtel YC, Bonaiti-Pellie C, Poisson N, Magnette J, Bechtel PR: A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther 1993;54:134-141.
41. Suhardjono D, Boutagy J, Shenfield GM: The effect of glucose on acetylation status. Br J Clin Pharmacol 1986;22:401-408.